4-hydroxy-2-phenylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-hydroxy-2-phenylpyridine
• 英文别名: 2-phenylpyridin-4-ol；2-phenyl-1H-pyridin-4-one
• 化学式: C₁₁H₉NO
• 分子量: 171.199
• InChiKey: HMNHOVLVFACRNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-hydroxy-2-phenylpyridine 在 palladium on activated charcoal ammonium formate 、 potassium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 18.17h， 生成 2-苯基吡啶
  参考文献：
  名称：

  Lowe, John A.; Ewing, Frank E.; Drozda, Susan E., Synthetic Communications, 1989, vol. 19, # 17, p. 3027 - 3036

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 作用下， 生成 4-hydroxy-2-phenylpyridine
  参考文献：
  名称：

  Borsche; Peter, Justus Liebigs Annalen der Chemie, 1927, vol. 453, p. 158

  摘要：

  DOI：

文献信息

• 8-Azabicyclo[3.2.1]octane derivatives
  申请人：Napier Elizabeth Susan

  公开号：US20070185156A1

  公开（公告）日：2007-08-09

  The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof or solvate thereof. The present invention also relates to a pharmaceutical composition comprising an 8-azabicyclo[3.2.1]octane derivative in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of the 8-azabicyclo[3.2.1]octane derivative in therapy.

  本发明涉及一种式I的8-氮杂双环[3.2.1]辛烷衍生物，其中每个取代基的定义如规范和声明中所述，或其药学上可接受的盐或溶剂。本发明还涉及一种药物组合物，其包括8-氮杂双环[3.2.1]辛烷衍生物与一种或多种药学上可接受的辅助剂混合，并且涉及在治疗中使用8-氮杂双环[3.2.1]辛烷衍生物。
• Structure-thermodynamics-relationships of hepatitis C viral NS3 protease inhibitors
  作者：Rachel M. Wypych、Steven R. LaPlante、Peter W. White、Stephen F. Martin

  DOI：10.1016/j.ejmech.2020.112195

  日期：2020.4

  Thermodynamic parameters were determined for structurally-related inhibitors of HCV NS3 protease to assess how binding entropies and enthalpies vary with incremental changes at the P2 and P3 inhibitor subsites. Changing the heterocyclic substituent at P2 from a pyridyl to a 7-methoxy-2-phenyl-4-quinolyl group leads to a 710-fold increase in affinity. Annelating a benzene ring onto a pyridine ring leads

  确定了HCV NS3蛋白酶的结构相关抑制剂的热力学参数，以评估结合熵和焓如何随P2和P3抑制剂亚位点的增量变化而变化。将P2处的杂环取代基从吡啶基更改为7-甲氧基-2-苯基-4-喹啉基可导致亲和力增加710倍。将苯环退火到吡啶环上会导致喹啉衍生的抑制剂具有更高的亲和力，但每个配体对的焓和熵贡献均明显不同。在P2的杂环的C2处引入苯基均匀地导致具有更有利的结合熵的较高亲和力类似物，而在P2的喹啉环的C7处加入甲氧基提供具有更有利的结合焓的衍生物。对于缺少2-苯基取代基的抑制剂的结构变化观察到显着的焓/熵补偿，而当存在2-苯基基团时，结合焓和熵的有利变化都伴随着结构修饰。总的来说，在P2处具有2-苯基-4-喹啉基的抑制剂的结合能受熵作用支配，而相应的去甲苯基类似物的结合主要是由焓驱动的。值得注意的是，对于这组抑制剂，从熵驱动的缔合转变为焓驱动的缔合也与替代的结合模式相关。当P3上侧链的空间体积从氢原子增加到
• PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2022782A1

  公开（公告）日：2009-02-11

  The present invention relates to a method for preparing a syn-form piperidine compound represented by general formula [I]: wherein, bold lines represent bonds in which substituents at positions 2 and 4 of a piperidine ring are in the syn configuration, and the other symbols have the same meaning as defined below, or a salt thereof, comprising: reducing a compound represented by general formula [II]: wherein, ring A represents an optionally substituted benzene ring, R2 represents a hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, and M represents an alkaline metal or hydrogen atom.

  本发明涉及一种制备由通用式[I]表示的同构吡啶化合物的方法：其中，粗线表示吡啶环的2位和4位取代基处于同构构象，其他符号的含义如下定义，或其盐，包括：还原由通用式[II]表示的化合物：其中，环A表示一个可选择取代的苯环，R2表示氢原子、可选择取代的羟基、可选择取代的氨基、可选择取代的烷基、取代的羰基或卤素原子，M表示碱金属或氢原子。
• METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS
  申请人：Matsumae Hiroaki

  公开号：US20090198052A1

  公开（公告）日：2009-08-06

  The present invention relates to a method for preparing a syn-form piperidine compound represented by general formula [I]: wherein, bold lines represent bonds in which substituents at positions 2 and 4 of a piperidine ring are in the syn configuration, and the other symbols have the same meaning as defined below, or a salt thereof, comprising: reducing a compound represented by general formula [II]: wherein, ring A represents an optionally substituted benzene ring, R 2 represents a hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, and M represents an alkaline metal or hydrogen atom.

  本发明涉及一种制备一种由通式[I]表示的syn型哌啶化合物的方法：其中，粗线表示哌啶环的2和4位取代基处为syn构型，其他符号的含义如下所定义，或其盐，包括：还原由通式[II]表示的化合物：其中，环A表示可选取代的苯环，R2表示氢原子、可选取代的羟基、可选取代的氨基、可选取代的烷基、取代的羰基或卤素原子，M表示碱金属或氢原子。
• Development of <i>N</i>-Methyl-(2-arylquinolin-4-yl)oxypropanamides as Leads to PET Radioligands for Translocator Protein (18 kDa)
  作者：Chad Brouwer、Kimberly Jenko、Sami S. Zoghbi、Robert B. Innis、Victor W. Pike

  DOI：10.1021/jm5007947

  日期：2014.7.24

  Translocator protein (18 kDa), known as TSPO, is a recognized biomarker of neuroinflammation. Radioligands with PET accurately quantify TSPO in neuroinflammatory conditions. However, the existence of three human TSPO genotypes that show differential affinity to almost all useful TSPO PET radioligands hampers such studies. There is an unmet need for genotype-insensitive, high-affinity, and moderately lipophilic TSPO ligands that may serve as leads for PET radioligand development. To address this need, we varied the known high-affinity TSPO ligand (l)-N,N-diethyl-2-methyl-3-(2-phenylquinolin-4-yl)propanamide in its aryl scaffold, side chain tether, and pendant substituted amido group while retaining an N-methyl group as a site for labeling with carbon-11. From this effort, oxygen-tethered N-methyl-aryloxypropanamides emerged as new high-affinity TSPO ligands with attenuated lipophilicity, including one example with attractive properties for PET radioligand development, namely N-methyl-N-phenyl-2-[2-(pyridin-2-yl)quinolin-4-yl]oxy}propanamide (22a; rat K-i = 0.10 nM; human TSPO genotypes K-i = 1.4 nM; clogD = 4.18).